PepGen (PEPG) Insider Habib Dable Buys 34,000 Shares

Habib Dable and Insiders Add Shares of PepGen Inc.

PepGen Inc. (NASDAQ:PEPG) recently saw a coordinated round of insider transactions when Habib Dable and several colleagues added to their personal holdings. On June 18, 2026, Dable picked up 34,000 shares of the biotechnology firm. This transaction follows a pattern of internal purchases across the Boston-based enterprise as executives put their own money on the line.

Coordinated Insider Transactions at PepGen Inc.

The mid-June filing period revealed that Dable wasn't alone in increasing his stake. On the exact same date of June 18, 2026, Howard Mayer also picked up 34,000 shares. Joshua Resnick joined them by acquiring 34,000 shares. Mitchell Finer added 34,000 shares to his personal account, and Lisa Wyman rounded out the group by securing 34,000 shares as well. These parallel moves by multiple members of the leadership team give observers a clear look at internal sentiment.

Stock Price Trades Near Lower Bounds

On Tuesday, shares of PepGen changed hands around $1.83. The equity has experienced a wide trading band over the past year, reaching as high as $7.80 while sinking down to its 52-week low of $1.31. Market participants often track how executives react when a stock trades closer to its lower boundary than its peak.

Analysts Set New Price Targets

Wall Street firms continue to monitor the clinical-stage biotech firm closely. On September 9, 2026, HC Wainwright & Co. reiterated its buy rating on the stock with a price target of $20.00. Across the wider analyst community, the company holds a consensus recommendation of strong buy from a total of eight analysts, featuring a mean price target of $10.19 alongside a high target of $20.00.

Inside the Biotechnology Pipeline

Headquartered in Boston, Massachusetts, PepGen works on specialized oligonucleotide therapeutics aimed at severe neuromuscular and neurologic disorders. The enterprise focuses heavily on advancing treatments like PGN-EDODM1 and FREEDOM2-DM1, which are currently moving through Phase 2 clinical evaluation for myotonic dystrophy type 1. These ongoing trials form the core of the company's research efforts.

What to Watch at PepGen Inc.

Observers will look toward the next scheduled financial report on November 11, 2026, to gauge cash burn and trial progress. Insider transactions provide a window into executive confidence, though they reflect individual choices rather than broader market guarantees.